Drug Search Results
More Filters [+]

RO-6806127

Alternative Names: ro-6806127, ro6806127, ro 6806127
Latest Update: 2016-11-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MGLUR5 Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RO-6806127

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BP29276

P1

Completed

Healthy Volunteers

2015-01-01

Recent News Events

Date

Type

Title